PharmiWeb.com - Global Pharma News & Resources

Healthcare - Press Releases

Date Title Company
10-Jan-2024 Avance Clinical: Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner Avance Clinical
09-Jan-2024 Ablatus Creators of Luna launches crowfunding campaign inviting community to join the fight against uterine fibroids  Ablatus Creators of Luna
09-Jan-2024 AT-HOME APP LAUNCHES AS NHS REVEALS ALMOST 2M HOSPITALISED DUE TO UTI Newfoundland
09-Jan-2024 Nutrigene Launches Personalised Development Program to Intersect Genetics and Learning through DNA Nutrigene Modern Sciences Sdn. Bhd
09-Jan-2024 AMLo Biosciences publish pivotal data for diagnostic biomarker technology AMBLor® in identifying melanomas at low risk of metastasis AMLo Biosciences
08-Jan-2024 Bayer and RTW Investments lead Series D financing in Chinese biotech Ji Xing Pharmaceuticals Bayer and RTW Investments, LP (“RTW”)
08-Jan-2024 Cell and Gene Therapy Catapult announces successful renewal of its five-year funding from Innovate UK to further support the advanced therapies sector The Cell and Gene Therapy Catapult
08-Jan-2024 Type 2 Diabetes Market: Analysis Of Epidemiology, Industry Trends, Size, Share, And Future Forecast (2023-2033) IMARC Group
05-Jan-2024 LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in comp ADC Therapeutics
04-Jan-2024 The England areas with the longest distance to GP services Journo Research
04-Jan-2024 Single Cell RNA Sequencing Kits Market: Trends, Innovations, and Growth Opportunities Stringent Datalytics
03-Jan-2024 OncoZenge submits application for PRIME status in the EU OncoZenge
03-Jan-2024 Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults Mundipharma
03-Jan-2024 NICE publishes positive final draft guidance for Sanofi’s innovative medicine Rezurock® (belumosudil) for patients with chronic graft-versus-host disease (cGVHD) that will receive immediate funding through the Innovative Medicines Fund (IMF) Sanofi
03-Jan-2024 Longest strike in NHS history leaves local services ‘skating on the thinnest of ice’, warn NHS leaders NHS Confederation
02-Jan-2024 Swedish innovation evaluated for clinical diagnosis of pediatric leukemia Qlucore
02-Jan-2024 Metabolomics Market Growing at a CAGR of 14.9% Say, Roots Analysis rootsanalysis
02-Jan-2024 Market Dynamics of Temperature Monitoring Systems: Challenges and Future Prospects Markets and Markets
25-Dec-2023 Revolutionizing Healthcare: A Comprehensive Analysis of the MedTech Sector in 2024 Markets and Markets
20-Dec-2023 InnoScot Health believes Scotland must take advantage of Horizon funding for innovation success InnoScot Health